https://orcid.org/0000-0001-5503-2462
References
- Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.
- Prignano F. Itch in psoriasis: epidemiology, clinical aspects and treatment options. CCID. 2009;2:9–13.
- Callis Duffin K, Mason MA, Gordon K, et al. Characterization of patients with psoriasis in challenging-to-Treat body areas in the corrona psoriasis registry. Dermatology. 2021;237(1):46–55.
- Schön MP. Adaptive and innate immunity in psoriasis and other inflammatory disorders. Front Immunol. 2019;10:1764.
- Horváth S, Komlódi R, Perkecz A, et al. Methodological refinement of aldara-induced psoriasiform dermatitis model in mice. Sci Rep. 2019;9(1):3685.
- Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. IJMS. 2019;20(6):1475.
- Li B, Huang L, Lv P, et al. The role of Th17 cells in psoriasis. Immunol Res. 2020;68(5):296–309.
- von Stebut E, Boehncke W-H, Ghoreschi K, et al. IL-17A in psoriasis and beyond: cardiovascular and metabolic implications. Front Immunol. 2019;10:3096.
- Fitch E, Harper E, Skorcheva I, et al. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep. 2007;9(6):461–467.
- Lv J, Sharma A, Zhang T, et al. Pharmacological review on asiatic acid and its derivatives: a potential compound. SLAS Technol. 2018;23(2):111–127.
- Kavitha CV, Jain AK, Agarwal C, et al. Asiatic acid induces endoplasmic reticulum stress and apoptotic death in glioblastoma multiforme cells both in vitro and in vivo. Mol Carcinog. 2015;54(11):1417–1429.
- Nagoor Meeran MF, Goyal SN, Suchal K, et al. Pharmacological properties, molecular mechanisms, and pharmaceutical development of asiatic acid: a pentacyclic triterpenoid of therapeutic promise. Front Pharmacol. 2018;9:892.
- Percie Du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. BMC Vet Res. 2020;16(1):242
- Huang S-S, Chiu C-S, Chen H-J, et al. Antinociceptive activities and the mechanisms of anti-Inflammation of asiatic acid in mice. Evid Based Complement Alternat Med. 2011;2011:1–10.
- Cao S-y, Wang W, Nan F-F, et al. Asiatic acid inhibits LPS-induced inflammatory response in endometrial epithelial cells. Microb Pathog. 2018;116:195–199.
- Oishi N, Iwata H, Kambe N, et al. Expression of precipitating factors of pruritus found in humans in an imiquimod-induced psoriasis mouse model. Heliyon. 2019;5(6):e01981.
- van der Fits L, Mourits S, Voerman JSA, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009;182(9):5836–5845.
- Liu T, Li S, Ying S, et al. The IL-23/IL-17 pathway in inflammatory skin diseases: from bench to bedside. Front Immunol. 2020;11:594735.
- Jabeen M, Boisgard A-S, Danoy A, et al. Advanced characterization of imiquimod-induced psoriasis-like mouse model. Pharmaceutics. 2020;12(9):789.
- Bylka W, Znajdek-Awiżeń P, Studzińska-Sroka E, et al. Centella asiatica in cosmetology. pdia. 2013;1:46–49.
- Sampson JH, Raman A, Karlsen G, et al. In vitro keratinocyte antiproliferant effect of centella asiatica extract and triterpenoid saponins. Phytomedicine. 2001;8(3):230–235.
- Nakamura M, Toyoda M, Morohashi M. Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors. Br J Dermatol. 2003;149(4):718–730.
- Weaver CT, Elson CO, Fouser LA, et al. The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. Annu Rev Pathol. 2013;8(1):477–512.
- Schön MP, Erpenbeck L. The interleukin-23/interleukin-17 axis links adaptive and innate immunity in psoriasis. Front Immunol. 2018;9:1323.
- Gaffen SL, Jain R, Garg AV, et al. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585–600.
- Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016;12(1):49–62.